Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00080496 · ClinicalTrials.gov registry record · Phase 3

Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia

A Phase 3 study of Bacterial Pneumonia, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 3
Development phase
430
Enrollment target
20
Study locations

NCT00080496: Completed Phase 3 study of Bacterial Pneumonia, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

NCT00080496 is a Phase 3 study of Bacterial Pneumonia that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 430 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00080496, a Phase 3 study of Bacterial Pneumonia, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
430 participants
Enrollment target
20
Study locations

Study Summary

To compare the efficacy and safety of the tigecycline regimen with that of the imipenem/cilastatin regimen in subjects with nosocomial pneumonia.

Conditions Studied

Bacterial Pneumonia

Interventions

  • DRUG Tigecycline
  • DRUG Imipenem
  • DRUG Cilastatin

Study Locations (20)

Arizona

  • - Phoenix
  • - Phoenix
  • - Scottsdale
  • - Scottsdale

California

  • - Martinez
  • - Modesto
  • - Modesto
  • - National City

Florida

  • - Bay Pines
  • - Crystal River
  • - Gainesville
  • - Orlando

Georgia

  • - Atlanta
  • - Augusta
  • - Roswell

Illinois

  • - Chicago
  • - Springfield
  • - Springfield

Louisiana

  • - New Orleans
  • - Shreveport

Trial Details

FieldValue
Enrollment Target 430 participants
Start Date 2003-07
Est. Completion 2006-12
Phase Phase 3
Wyeth is now a wholly owned subsidiary of Pfizer

167 total trials

What the finished NCT00080496 record still lists

NCT00080496 is an interventional study that assigns participants to a tested intervention. The registered 430 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% lower).

The record links to 1 condition, with Bacterial Pneumonia appearing as the primary indexed condition, and to 3 interventions - of which Tigecycline is the first listed.

NCT00080496 names 20 study sites across 6 states, led by Arizona, California, Florida.

Frequently Asked Questions

What is clinical trial NCT00080496 about?

NCT00080496 is a clinical study titled "Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia". To compare the efficacy and safety of the tigecycline regimen with that of the imipenem/cilastatin regimen in subjects with nosocomial pneumonia.

What is the current status of trial NCT00080496?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 430 participants. The study started on 2003-07. Estimated completion is 2006-12.

What conditions does trial NCT00080496 study?

This clinical trial studies the following conditions: Bacterial Pneumonia.

What interventions are being tested in trial NCT00080496?

The interventions under investigation include: Tigecycline (DRUG), Imipenem (DRUG), Cilastatin (DRUG).

Who is sponsoring clinical trial NCT00080496?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00080496 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT00080496's enrollment target sits among peer trials

430 877th of 2000 higher than 1,123 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05327023 · 430 participants · Phase 1

    Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

  • NCT05457985 · 430 participants · NA

    Testing Adaptive Interventions to Improve Posttraumatic Stress Disorder Treatment Outcomes in Federally Qualified Health Centers

  • NCT05532982 · 430 participants

    Parkinson's Disease in Asian Americans

  • NCT05844891 · 430 participants · NA

    Telehealth-Enhanced Asthma Care for Home After the Emergency Room

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00080496, the US trial registry maintained by the National Library of Medicine. NCT00080496 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.